Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
eli lilly
indiana blog main
indiana top stories
life sciences
migraine
3
×
national blog main
teva pharmaceutical
amgen
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
detroit blog main
detroit top stories
drugs
fda
fremanezumab
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
adalimumab (humira)
aducanumab
aduro biotech
What
approval
3
×
drug
new
class
companies
fda
migraine
won
announced
approved
arguments
big
bio
biogen’s
biopharmaceutical
commercialized
competitors
convo
decades
decision
developed
drugs
earlier
eli
failures
headache
late
lilly
littered
make
marks
medicines
meeting
nash
neuro
news
oral
pain
potential
prevent
Language
Current search:
approval
×
migraine
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines